Results 41 to 50 of about 3,987 (159)
Longer Asthma Duration Is Associated With Elevated Non‐T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma
Allergy, EarlyView.Longer asthma duration is associated with increased airway non‐T2 inflammation and reduced airway and systemic T2 inflammation. Sputum CXCL9 is independently associated with duration and may predict a reduced poor response to anti‐IL‐4Rα therapy. Airway sampling and combined T2 and non‐T2 targeted strategies may be needed in long‐standing asthma. CXCL9,Freda Yang, Sujin Seo, Takehiro Hasegawa, Chloe I. Bloom, Nazanin Zounemat‐Kermani, Pankaj K. Bhavsar, Katie Raby, Ian M. Adcock, Sungho Won, Tae‐Bum Kim, Kian Fan Chung, on behalf of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) Consortium, M. I. Abdel‐Aziz, C. Auffray, Y. E. Badi, P. Bakke, A. T. Bansal, F. Baribaud, S. Bates, A. F. Behndig, E. H. Bel, J. Bigler, B. Billing, M. J. Boedigheimer, K. Bønnelykke, J. Brandsma, P. Brinkman, E. Bucchioni, D. Burg, A. Bush, M. Caruso, R. Chalekis, P. Chanez, B. Chaves, F. K. Chung, T. Checa, C. H. Compton, J. Corfield, D. Cunoosamy, A. D'Amico, B. Dahlén, B. De Meulder, R. Djukanovic, V. J. Erpenbeck, D. Erzen, K. Fichtner, L. J. Fleming, E. Formaggio, S. J. Fowler, U. Frey, M. Gahlemann, T. Geiser, V. Goss, Y. Guo, S. Hashimoto, J. Haughney, G. Hedlin, P. W. Hekking, T. Higenbottam, J. M. Hohlfeld, C. Holweg, I. Horváth, P. Howarth, A. J. James, R. G. Knowles, J. Kolmert, J. Konradsen, N. Krug, N. Lazarinis, C.‐X. Li, M. J. Loza, R. Lutter, A. Manta, S. Masefield, Maitland‐van der Zee Anke‐Hilse, J. G. Matthews, A. Mazein, R. J. M. Middelveld, M. Miralpeix, C. S. Murray, J. Musial, S. Mumby, D. Myles, B. Nordlund, H. Olsson, I. Pandis, S. Pavlidis, A. Platt, A. Postle, P. Powel, G. Praticò, M. Puig Valls, N. Rao, S. Reinke, J. Riley, A. Roberts, G. Roberts, A. Rowe, T. Sandström, J. P. R. Schofield, W. Seibold, D. E. Shaw, R. Sigmund, F. Singer, P. J. Skipp, M. Smicker, A. R. Sousa, M. Sparreman‐Mikus, P. J. Sterk, K. Sun, B. Thornton, A. Versi, N. H. Vissing, A. M. Wheelock, C. E. Wheelock, S. J. Wilson, V. Yasinska, Aliprantis Antonios, Allen David, Alving Kjell, P. Badorrek, Balgoma David, S. Ballereau, Barber Clair, Batuwitage Manohara Kanangana, Bautmans An, A. Bedding, A. F. Behndig, Beleta Jorge, A. Berglind, Bochenek Grazyna, Braun Armin, D. Campagna, Carayannopoulos Leon, C. Casaulta, A. Chaiboonchoe, Chaleckis Romanas, Davison Timothy, De Alba Jorge, Dekker Tamara, Delin Ingrid, P. Dennison, Dijkhuis Annemiek, Dodson Paul, Draper Aleksandra, K. Dyson, Edwards Jessica, L. El Hadjam, Emma Rosalia, C. Faulenbach, Flood Breda, G. Galffy, Gallart Hector, D. Garissi, J. Gent, M. Gerhardsson de Verdier, D. Gibeon, Gomez Cristina, Gove Kerry, Gozzard Neil, E. Guillmant‐Farry, E. Henriksson, Hewitt Lorraine, U. Hoda, Hu Richard, Hu Sile, X. Hu, E. Jeyasingham, K. Johnson, N. Jullian, Kamphuis Juliette, J. Kennington Erika, Kerry Dyson, G. Kerry, M. Klüglich, Knobel Hugo, J. Knox Alan, Kolmert Johan, J. R. Konradsen, Kots Maxim, Kretsos Kosmas, L. Krueger, Kuo Scott, Kupczyk Maciej, A.‐S Lantz, Larminie Christopher, L. X. Larsson, P. Latzin, N. Lazarinis, Lefaudeux Diane, N. Lemonnier, Li Chuan‐Xing, Lone‐Latif Saeeda, L. A. Lowe, Manta Alexander, Marouzet Lisa, Martin Jane, Mathon Caroline, L. McEvoy, Meah Sally, A. Menzies‐Gow, Metcalf Leanne, Meiser Andrea, Mikus Maria, Monk Philip, N. Mores, Naz Shama, K. Nething, Nicholas Ben, U. Nihlén, Nilsson Peter, R. Niven, B. Nordlund, S. Nsubuga, Pacino Antonio, Palkonen Susanna, L. Pahus, J. Pellet, Pennazza Giorgio, Petrén Anne, Pink Sandy, C. Pison, Rahman‐Amin Malayka, Ravanetti Lara, Ray Emma, Reinke Stacey, Reynolds Leanne, K. Riemann, Robberechts Martine, J. P. Rocha, C. Rossios, Russell Kirsty, Rutgers Michael, G. Santini, Santonico Marco, M. Saqi, Schoelch Corinna, S. Scott, N. Sehgal, A. Selby, Sjödin Marcus, Smids Barbara, Smith Caroline, Smith Jessica, M. Smith Katherine, P. Söderman, A. Sogbesan, F. Spycher, Staykova Doroteya, S. Stephan, J. Stokholm, K. Strandberg, M. Sunther, M. Szentkereszty, L. Tamasi, K. Tariq, Thörngren John‐Olof, Thorsen Jonathan, S. Valente, W. M. van Aalderen, Marianne van de Pol, C. M. van Drunen, Van Eyll Jonathan, Versnel Jenny, Vink Anton, C. von Garnier, A. Vyas, A. H. Wagener, Wald Frans, Walker Samantha, Ward Jonathan, Wetzel Kristiane, Wiegman Coen, Z. Weiszhart, Williams Siân, Yang Xian, Yeyasingham Elizabeth, W. Yu, W. Zetterquist, Z. Zolkipli, A. H. Zwinderman, Lega Italiano Anti Fumo, A. B. Aerocrine, N. V. Amgen, Merck Sharp, Martina Gahlemann, Luigi Visintin, Hazel Evans, Martine Puhl, Lina Buzermaniene, Val Hudson, Laura Bond, Pim de Boer, Guy Widdershoven, Ralf Sigmund, David Supple, Dominique Hamerlijnck, Jenny Negus, Juliёtte Kamphuis +298 morewiley +1 more sourceRapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
Medicina, 2019 A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy.Hiroaki Tsurumaki, Toshiyuki Matsuyama, Kazuma Ezawa, Yasuhiko Koga, Masakiyo Yatomi, Haruka Aoki-Saito, Kazuaki Chikamatsu, Takeshi Hisada +7 moredoaj +1 more sourceBenralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial
Journal of Asthma and Allergy, 2018 Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and ...Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M +6 moredoaj A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma
Clinical &Experimental Allergy, EarlyView.Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background
Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson +23 morewiley +1 more sourceClinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
Journal of Asthma and Allergy, 2022 Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health ...AlShareef S, McDonald CF, Lee Jdoaj Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study
Journal of the European Academy of Dermatology and Venereology, EarlyView.A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot +17 morewiley +1 more sourceDifferences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?
International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 769-777, August 2026.Key Points
In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...Marjolein Cornet, Peter W. Hellings, Martin Desrosiers, Martin Wagenmann, Richard Follows, Laura Walrave, Luz Adriana Jimenez, Lee Tombs, Dawn Edwards, Peter Howarth, Joseph K. Han +10 morewiley +1 more sourceSystemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review
International Forum of Allergy &Rhinology, Volume 16, Issue 8, Page 852-879, August 2026.ABSTRACT Background
Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.Andrew Thamboo, Deanna Gigliotti, Eugenio De Corso, Stella Lee, Benjamin S. Bleier, Christopher J. Chin, Marie‐Noelle Corriveau, Valerie Hox, Claire Hopkins, Peter H. Hwang, Arif Janjua, Ludger Klimek, Daniel Lee, John Lee, Amber Luong, Geoffrey Mortuaire, Joaquim Mullol, Zara M. Patel, John Scott, Doron Sommer, Leigh Sowerby, Marc Tewfik, Beatrice Voizard, Martin Wagenmannm, Sarah K. Wise, Jonathan Yip, Quirina Thompson, Martin Desrosiers, Yvonne Chan +28 morewiley +1 more sourcePrediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort
Arthritis &Rheumatology, Volume 78, Issue 8, Page 1710-1717, August 2026.Objective
Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, and throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common. The aim of this study was to develop predictive models for vasculitis Matthias Papo, Pauline Martinot, Renato A. Sinico, Vítor Silvestre‐Teixeira, Nils Venhoff, Maria‐Letizia Urban, Michele Iudici, Juliane Mahrhold, Francesco Locatelli, Giulia Cassone, Franco Schiavon, Benjamin Seeliger, Thomas Neumann, Claudia Feder, Matthieu Groh, Chiara Marvisi, Maxime Samson, Thomas Barba, David Jayne, Arianna Troilo, Jens Thiel, Bernhard Hellmich, Sara Monti, Carlomaurizio Montecucco, Carlo Salvarani, Jean‐Emmanuel Kahn, Bernard Bonnotte, Cécile‐Audrey Durel, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, Giacomo Emmi, Augusto Vaglio, Raphaël Porcher, Benjamin Terrier, on behalf of the French Vasculitis Study Group and the Eosinophilic Granulomatosis with Polyangiitis European Study Group +35 morewiley +1 more source
